BioCryst Pharmaceuticals | BCRX - Biaya Penjualan





Biaya Penjualan Perubahan Tanggal
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Chugai Pharma JPY 92.79B 5.23B 2026-03
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Gilead Sciences USD 1.44B 174M 2026-03
GlaxoSmithKline GBP 1.88B 736M 2026-03
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Incyte USD 104.5M 16.68M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
Karyopharm Therapeutics USD 1.48M 35.95M 2025-12
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Novavax USD 22.1M 608K 2025-12
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03